Nothing Special   »   [go: up one dir, main page]

Latest News for: relapse monumental

Edit

TALVEY®▼ (talquetamab) demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

Pharmiweb 17 Jun 2024
Long-term efficacy and safety results from the Phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
Edit

New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with ...

Victoria Advocate 12 Dec 2023
Analysis from MonumenTAL-1 study showed patients with relapsed or refractory multiple myeloma treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including CAR-T.
Edit

Sarah Cannon Research Institute to Present Latest Research Insights at the 2023 ASH Annual Meeting ...

Hastings Tribune 07 Dec 2023
Jeffrey Matous, MD, Colorado Blood Cancer Institute, is first author on an oral presentation titled, “ Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
Edit

Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent ...

Longview News-Journal 03 Jun 2023
Analysis of Infections and Parameters of Humoral Immunity in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab Monotherapy in MonumenTAL-1 ... Pivotal Phase 2 MonumenTAL-1 ...
Edit

Health & Wellness: Psychology-based tips to stick to your New Year’s resolutions

Provo Daily Herald 28 Dec 2022
However, almost all of the veterans that were addicted to heroin in Vietnam became sober immediately upon returning home; a mere 5% of these veterans relapsed ... the United States relapsed at some point.
Edit

Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in ...

Victoria Advocate 10 Dec 2022
Talquetamab, which is given by subcutaneous injection, is currently being evaluated in the Phase 1/2 MonumenTAL-1 clinical study for the treatment of relapsed or refractory multiple myeloma ...
Edit

Research Highlights Cutting-Edge New Treatments for Blood Disorders

Victoria Advocate 10 Dec 2022
Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Phase 1/2 Results from MonumenTAL-1.
Edit

Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients ...

Victoria Advocate 09 Dec 2022
NCT04634552)�in patients with relapsed or refractory multiple myeloma who have received more than three prior lines of therapy.1�The first presentation of Phase 2 results from the MonumenTAL-1 study ...
Edit

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and ...

Victoria Advocate 03 Nov 2022
In addition, this year's ASH press program will feature data from the Phase 1/2 MonumenTAL-1 talquetamab (GPRC5DxCD3 bispecific antibody) study in relapsed or refractory multiple myeloma (RRMM), and ...
  • 1

Most Viewed

×